Press Release Archive

07.28.2015

PFIZER REPORTS SECOND-QUARTER 2015 RESULTS

07.22.2015

Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility

07.08.2015

Pfizer’s Centers For Therapeutic Innovation And Jeffrey Modell Foundation Announce Collaboration to Help Advance Immunological Research

07.07.2015

Pfizer Begins Phase 2b Study Of Its Investigational Multi-antigen Staphylococcus aureus Vaccine In Adults Undergoing Elective Spinal Fusion Surgery

07.02.2015

Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets

06.25.2015

Joseph J. Echevarria Elected To Pfizer’s Board Of Directors

06.25.2015

Pfizer Declares 28-Cent Third-Quarter 2015 Dividend

06.24.2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA® for Adolescents and Young Adults 16 through 23 Years of Age

06.23.2015

Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

06.23.2015

Pfizer Invites Public To View And Listen To Webcast Of July 28 Conference Call With Analysts

06.23.2015

New Online Community, Quitter’s Circle, Helps Smokers Trade Cigarettes for Real-Time Support

06.22.2015

Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline

06.11.2015

Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder

06.10.2015

Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)

06.08.2015

Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology

06.04.2015

Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging Through New Campaign

05.30.2015

Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

05.29.2015

Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

05.28.2015

Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

05.28.2015

Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health

05.19.2015

Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

05.14.2015

Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira

05.14.2015

Bar Ilan University to work with Pfizer Inc. to evaluate drug delivery via DNA Nanorobots

05.14.2015

Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors

05.13.2015

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

05.11.2015

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

05.06.2015

Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat

05.05.2015

23andMe Launches Lupus Research Community in Collaboration with Pfizer Inc.

04.28.2015

PFIZER REPORTS FIRST-QUARTER 2015 RESULTS

04.23.2015

Pfizer Hosts Annual Meeting Of Shareholders

04.21.2015

Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

04.21.2015

Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

04.20.2015

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

04.16.2015

Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders

04.16.2015

Pfizer Launches 2014 Integrated Annual Review

04.15.2015

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

04.14.2015

REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

04.09.2015

Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research

04.07.2015

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

04.06.2015

Kathrin U. Jansen, Ph.D., to Lead Pfizer’s Vaccine Research and Development Unit

03.30.2015

Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

03.26.2015

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.23.2015

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

03.20.2015

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

03.18.2015

Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

03.12.2015

Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia

03.03.2015

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

02.26.2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk